Influenza Vaccine Tetra Myl

B/Phuket/3073/2013-like virus, the active ingredient in Influenza Vaccine Tetra Myl, is a vaccine presented as a vaccine for intramuscular or subcutaneous use. It induces immunity to protect against influenza B infections caused by the B/Phuket/3073/2013-like and B/Austria/1359417/202 strains in individuals at risk.

GNH USA supplies Influenza Vaccine Tetra Myl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, providing reliable global distribution and regulatory compliance.

Influenza Vaccine Tetra Myl is used to prevent influenza B virus infections, a major cause of seasonal flu. - Influenza B (B/Phuket/3073/2013-like strain): prevents illness and complications in at‑risk populations. - Influenza B (B/Austria/1359417/202 strain): reduces incidence of disease in individuals receiving the vaccine. - Seasonal influenza caused by B lineages: lowers overall community transmission when used in vaccination programs.

Common and serious adverse reactions may occur after administration of Influenza Vaccine Tetra Myl.

Common Side Effects: - Injection site pain - Redness at the injection site - Swelling at the injection site - Low‑grade fever

Serious or Rare Side Effects: - Anaphylaxis - Guillain‑Barré syndrome - Seizures - High‑grade fever

Before administering Influenza Vaccine Tetra Myl, consider the following precautions. - Assess allergy history: avoid in persons with severe hypersensitivity to any vaccine component. - Defer vaccination: postpone in individuals with acute moderate or severe illness. - Monitor after injection: observe for at least 15 minutes for immediate reactions. - Use caution in immunocompromised patients: vaccine may elicit reduced immune response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Influenza Vaccine Tetra Myl may interact with certain medications or other vaccines.

Major Interactions (Avoid): - Live attenuated vaccines: avoid concurrent administration due to potential interference. - Immunoglobulin therapy: may reduce vaccine effectiveness if given within 2 weeks before or after vaccination.

Moderate Interactions (Monitor Closely): - Antipyretics (acetaminophen, ibuprofen): may blunt antibody response if taken prophylactically. - Immunosuppressive drugs (e.g., corticosteroids, chemotherapy): may diminish immune response, monitor seroconversion. - Antihistamines: may mask early allergic signs, observe patient closely.